Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.
Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis
The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.
Skin clearance appeared within one month, itch relief within two weeks
Significant skin clearance was observed as early as one month into treatment, while significant itch improvement emerged within two weeks. According to University of Maryland dermatology chair Shawn G. Kwatra, patients on lebrikizumab achieved meaningful pain improvement at nearly three times the rate of placebo.
Nearly 80% of patients reported satisfaction with hand clearance at Week 16
Using the validated Atopic Hand Dermatitis Clearance Satisfaction (AHDCS) scale -- described as first-of-its-kind patient satisfaction data for moderate-to-severe hand AD -- significantly more EBGLYSS-treated patients reported being satisfied or very satisfied with hand clearance than those on placebo.
Safety profile remained consistent with no new signals
Treatment-emergent adverse events occurred in 41.8% of EBGLYSS patients versus 39.6% on placebo, all mild or moderate. The most common adverse reactions (≥5%) were nasopharyngitis and upper respiratory tract infection. Discontinuation due to adverse events was lower on EBGLYSS at 0.9% versus 2.7% on placebo.
Lilly has filed the data with FDA, targeting a label expansion
Lilly has submitted the ADtouch results to the U.S. Food and Drug Administration and plans submissions to additional global regulators, seeking a potential label update covering localized AD with moderate-to-severe hand and foot involvement. Up to 60% of AD patients have hand involvement and roughly 30% also have foot involvement, per the company.
Almirall to present five-year durability data from separate EBGLYSS trial
Almirall, which holds European commercialization rights for EBGLYSS in dermatology, will present five-year results from the Phase 3b ADlong trial at EADV, reinforcing previously reported four-year data on long-term durability in adults with moderate-to-severe AD. Lilly retains exclusive EBGLYSS rights across the U.S. and all markets outside Europe.
EBGLYSS already covers nearly 95% of U.S. commercial plans
EBGLYSS, an IL-13 inhibitor approved in the U.S., Japan and Canada in 2024 and in the EU in 2023, gained FDA approval in June 2026 for an every-eight-week maintenance dosing option alongside its existing monthly regimen. Lilly has secured coverage with all three major national pharmacy benefit managers.